Seres Therapeutics

$19.04
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.25 (+1.33%) Today
$0.00 (0.00%) As of 10:43 AM UTC after-hours

Why Robinhood?

You can buy or sell MCRB and other stocks, options, and ETFs commission-free!

About MCRB

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA. The listed name for MCRB is Seres Therapeutics, Inc. Common Stock.

CEO
Eric D. Shaff
Employees
108
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
1.95B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.06M
High Today
$19.58
Low Today
$17.67
Open Price
$18.93
Volume
1.19M
52 Week High
$38.50
52 Week Low
$2.52

MCRB Earnings

-$0.48
-$0.32
-$0.16
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Mar 2, Pre-Market
Preview Earnings Call

You May Also Like

IMPX
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure